Drug Profile
Research programme: anti-infectives - Emergent BioSolutions
Alternative Names: 2-pyridone based topoisomerase inhibitors (EV-035); EBX 205; EV 035 series - Emergent BioSolutions; EV-021; EV-035; EV-035a; EV-035b; EV-035c; EV-075; EV-086; GC-0146; GC-061; GC-063; GC-072Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Evolva Biotech
- Developer Emergent BioSolutions; United States Army Research Laboratory
- Class Antibacterials; Pyridones; Small molecules
- Mechanism of Action Immunomodulators; Type II bacterial DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anthrax; Burkholderia infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
- Discontinued Ebola virus infections; Escherichia coli infections; Influenza virus infections; Mycoses
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Anthrax in USA (PO)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Burkholderia infections in USA (PO)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (PO)